News Vaderis drug lends hope to patients with bleeding disease HH... A trial of Vaderis' AKT inhibitor engasertib finds it could be the first effective treatment for rare disease hereditary haemorrhagic telangiectasia.
News Platform tests commercial algorithms for NHS use for bias A platform that can test whether AI algorithms developed for NHS applications are fit for purpose and free of bias has shown its value in a new study.
News FDA starts priority review of BeOne's Venclexta rival BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.
News Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.
News Novo Nordisk files Wegovy product that claimed rapid voucher Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.
News Sanofi's Paris HQ raided in tax fraud probe Sanofi's headquarters in Paris has been raided as part of an investigation into a financing deal, said to be related to a historical acquisition.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.